Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2014

View Archived Issues

Redx Pharma and AstraZeneca to target genetic drivers of tumor growth and survival

Ludwig Cancer Research and Cancer Research Institute collaborate with VentiRx on motolimod trial

Sirona Biochem reports preclinical data for SBM-TFC-039

Herbosomes of P. granatum extracts to enhance bioavailability

RedHill Biopharma begins phase III study of RHB-102 for gastroenteritis

Novira advances NVR-1221 for HBV infection into phase Ib studies

Lilly's insulin peglispro shows HbA1c superiority over insulin glargine in type 1 diabetes

Conatus Pharmaceuticals begins two phase II trials of emricasan

MITOCARE trial does not demonstrate a protective effect for TRO-40303

Japanese researchers divulge new anti-semaphorin 3A MAbs

AstraZeneca presents promising clinical and non-clinical results for AZD-0914

Tricida confirms new clinical candidate for cardiorenal disease

Aesculap Biologics confirms first human implantation of Novocart 3D

Recro Pharma to close phase II pain trial of intranasal dexmedetomidine following interim analysis

Kamada's inhaled API misses endpoints in phase II/III trial

Chugai Pharmaceutical launches ALK inhibitor Alecensa

Tracon Pharmaceuticals begins phase II trial of TRC-105 in soft tissue sarcoma

FDA approves Keryx Biopharmaceuticals' ferric citrate

Soligenix acquires hypericin photodynamic therapy

FDA accepts filing of Actavis' NDA for ceftazidime/avibactam

Researchers sequence Ebola virus genomes from current outbreak

FDA removes partial clinical hold on ipafricept

Allergan discloses new S1P1 receptor modulators

NIAID's Ebola vaccine is first to provide durable protection in macaques

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...